The PIP Framework provides a structured and transparent system for sharing benefits arising from the sharing of influenza viruses with pandemic potential.
Section 6 of the Framework establishes a Benefit Sharing System that includes many elements that are to be made available to countries based on public health risk and need. Benefits include, but are not limited to, laboratory and surveillance capacity building, regulatory capacity building, establishment of preparedness stockpiles, and transfer of technology.
One benefit of particular importance for strengthening preparedness and response capacities in developing countries is the Partnership Contribution. It is an annual cash contribution to WHO by influenza vaccine, diagnostic and pharmaceutical manufacturers who use the WHO Global Influenza Surveillance and Response System (GISRS). The Framework specifies that the funds will be used for activities that strengthen global readiness for and response to pandemic influenza.
In order to facilitate benefit sharing by certain entities, Member States established a Standard Material Transfer Agreement 2 (SMTA2). These are legally-binding contracts that are to be negotiated by WHO with non-GISRS recipients of PIP biological materials (PIP BM) that may include influenza vaccine, diagnostic and pharmaceutical manufacturers, biotech firms, and research and academic institutions. Recipients are to assess the benefits they can contribute to the PIP benefit sharing system on the basis of their nature and capacity. The benefits to be shared may include:
- donations and/or reserve for purchase by WHO at affordable prices, of pandemic influenza vaccine, antiviral medicines or other pandemic related products;
- support to strengthen influenza laboratory and surveillance capacities in developing countries;
- licenses to technology relevant to the production of pandemic related products.
More examples of benefit sharing options may be found in Annex 2 of the PIP Framework.